Abstract
The STOP study was the first randomized trial of primary stroke prevention in sickle cell disease (Hb SS). 130 Hb SS children, age 2-16, at risk for stroke by Transcranial Doppier (TCD) were randomized to standard care (STC) (n=67) or transfusion (Tx)(n=63). There were no significant clinical or hématologie differences between the two groups except for a lower Hb (7.2 vs 7.6 g/dl, p=.001 ) and Hct (20.4 vs 21.7%, p=.002) in the Tx arm. Tx arm patients (transfused every 3-4 weeks to maintain Hb S
Original language | English (US) |
---|---|
Journal | Blood |
Volume | 96 |
Issue number | 11 PART II |
State | Published - 2000 |
Externally published | Yes |
ASJC Scopus subject areas
- Hematology